2026
Sustainable Pharma Is the New Competitive Baseline
A January 2026 panel interview emphasizes that dismissing sustainability undermines trust, talent, and long-term viability. The discussion frames sustainability as future-proofing: reducing risk exposure while improving efficiency and credibility across global supply chains. Aurigene's voice underscores the shift from compliance to competitive differentiation—built into day-to-day operations.
Read More2025
Aurigene Highlights PROTAC-Driven RIPK2 Degrader Discovery at DDC 2025
Dr. Gayathri Ramaswamy, Global Head of Discovery Services at Aurigene Pharmaceutical Services, presented Aurigene’s rapid design and synthesis of RIPK2 degraders at Drug Discovery Chemistry (DDC) 2025. The session showcased the company’s proprietary partial PROTAC library, rational degrader design strategies, and integrated discovery capabilities that accelerate targeted protein degradation research.
Read MoreFrom Cell Line to Clinic: A Faster Bispecific Pathway
Aurigene showcased accelerated bispecific antibody execution enabled by a state-of-the-art biologics facility and high-performance upstream/downstream strategies, including N-1 perfusion for high-density cell cultures plus optimised filtration and purification. The milestone, IND clearance through patient dosing in a year, signals a partner-ready pathway for next-gen biologics programmes.
Read MoreAurigene Introduces CHEESE Database to Accelerate Hit Identification
Aurigene Pharmaceutical Services has launched the Aurigene Virtual Library on the CHEESE (Chemical Exploration Engine for Similarity & Substructure Exploration) platform. The database streamlines hit identification and strengthens early discovery workflows, empowering researchers with seamless access to high-quality chemical space while reducing reliance on external vendors for compound procurement.
Read MoreRIPK2 Degraders: From Concept to Data, Faster
As degrader programmes scale, timelines and specificity have become the differentiators. Aurigene's RIPK2 degrader work, presented at DDC 2025, showcases a speed-focused workflow built on an in-house partial PROTAC library and computational design. The result: faster optimisation cycles and decision-ready profiling for next-generation immunology pipelines.
Read MoreA Faster DMTA Playbook for Targeted Degradation
At DDC 2025, Aurigene outlined a repeatable, speed-focused path to targeted protein degradation: design, rapid synthesis, and integrated assessment of RIPK2 degraders using a proprietary partial PROTAC library. The result is a compressed discovery cycle with earlier clarity on specificity and profiling, enabling teams to move from concept to actionable degrader series with confidence.
Read MoreBuilding Supply Chain Confidence Beyond a Single Region
As pharma diversifies supply chains, Aurigene is positioning India as a credible global base for small molecules and biologics through high-quality infrastructure and digitised operations. CEO Akhil Ravi highlights how Aurigene's quality compliance track record and broad market access enable biotech and pharma teams to move innovations from idea to patient with less friction.
Read MoreAurigene Advances AI-Driven Molecular Design
Aurigene presented its explainable AI framework at Discovery & Development Europe 2025, highlighting how AI models integrated with physics-based simulations can refine molecular design. By combining computational intelligence with scientific rigour, the platform helps discovery teams identify promising candidates faster while maintaining clarity in prediction outcomes.
Read MoreAurigene Launches CHEESE to Speed Hit Identification
Aurigene Pharmaceutical Services launched the Aurigene Virtual Library on the CHEESE platform (Chemical Exploration Engine for Similarity & Substructure Exploration) to accelerate hit identification in drug discovery. By enabling rapid similarity and substructure searches across a curated chemical space, the platform helps teams shorten early cycles and move to design decisions faster.
Read MoreRight-Fit Peptide Manufacturing Strategy Wins Time
Peptide pipelines are accelerating, but manufacturing strategy must match project timelines and target scale. At TIDES Europe 2025, Aurigene shared how flexible platforms and strong analytical capabilities reduce complexity risk and smooth technology transfer. The focus: selecting the right approach early to protect quality and compress development cycles.
Read MoreCRDMO Reform Signals a Partner-Led Era
With CRDMO leaders aligning to raise standards and global competitiveness, BioSpectrum's coverage reflects a market that is maturing beyond capacity into capability. Aurigene Pharmaceutical Services is positioned within this forward motion, supporting sponsors with integrated scientific execution and quality-first delivery that strengthens confidence across development and manufacturing pathways.
Read MoreChina’s India headache: The growing pharmaceutical industry
Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desire to diversify from China. These companies are investing in advanced technologies and specialized capabilities, particularly in biologics and complex chemistry, to capture a larger share of the global market. Aurigene pharmaceutical service, featured among the Top CDMO Companies, has been a key player in this evolution, recognized in prominent media such as The Economic Times.
Read More2024
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx announce potential partnership for joint development of affordable anti-malarial drug
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), and its CRDMO arm Aurigene Pharmaceutical Services Limited (Aurigene), today announced that they have signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc., a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, a novel mechanism of action for the development and commercialization of affordable anti-malarial drug in in the U.S., Europe, and in low and middle-income countries. The MoU remains subject to signing of a definitive agreement.
Read MoreAurigene Pharmaceutical Services Limited, a global CRDMO, and Edity announce a strategic collaboration in cell therapy
Aurigene Pharmaceutical Services Limited (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), will provide discovery services to Edity Therapeutics Limited (Edity) in cell therapy. Dr. Reddy’s Laboratories Limited, Aurigene’s parent company, recently made a strategic investment in Edity, a biotechnology company based in Israel.
Read MoreAurigene Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics facility offering process development and clinical scale manufacturing capabilities
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with process & analytical development and small scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical requirements. The process and analytical development laboratories are now operational while the commissioning of manufacturing capacity will be completed later in 2024.
Read MoreAurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services
Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership.
Read MoreAurigene Pharmaceutical Services Ltd. introduces Aurigene.AI, an artificial intelligence (AI) and machine learning (ML) assisted drug discovery platform
Aurigene.AI combines advanced physics-based simulation, generative and predictive AI models, and CADD (Computer-Aided Drug Design) in one platform, allowing users to pick the appropriate algorithms for a given application. The modular platform also consists of a meticulously curated database of 180 million compounds and 1.6 million validated bioassay data points. This database is ever-expanding and serves as training data for the platform.
Read More2023
Aurigene Pharmaceutical Services to invest Rs 330 crore in Genome Valley
Aurigene Pharmaceutical Services, a contract research, development, and manufacturing services organisation and a step-down subsidiary of Dr Reddy's Laboratories, has decided to establish a development and manufacturing facility focused on niche areas like therapeutic proteins, antibodies, and viral vectors in Hyderabad.
Read MoreAurigene Pharmaceutical Services to expand biologics CDMO capacity with a new biomanufacturing facility
Aurigene is investing $40m Mn USD in an R&D and pilot scale facility as a first step towards a series of strategic investments. Complemented by exclusive access to large-scale GMP commercial manufacturing capacity including fill-finish.
Read More2022
Aurigene Pharmaceutical Services, Dr. Reddy's Laboratories and DNDi to explore joint opportunities to develop affordable and life-saving new drugs for Neglected Tropical Diseases
Potential partnership to explore new therapeutic solutions and serve unmet needs of patients in Neglected Tropical Diseases in LMICs and beyond.
Read MoreAurigene Pharmaceutical Services Launches its New Branding at CPHI North America
Aurigene has been established as a wholly-owned subsidiary of Dr. Reddy’s through the merger of Aurigene Discovery Services and Dr. Reddy’s Custom Pharma Services (CPS). The launch of the brand happened during the pandemic and it is therefore the first opportunity for the team to exhibit the new brand to its customers.
Read More2021
Aurigene Pharmaceutical Services Limited (APSL) invests in adding Large Molecule Discovery and Development Services
Aurigene Pharmaceutical Services Limited, a wholly-owned subsidiary of Dr. Reddy’s expands its existing discovery and development capacities with the inauguration of a biotherapeutics discovery facility in Hyderabad, India.
Read MoreDeepMatter to trial its DigitalGlassware® platform with Aurigene Pharmaceutical Services
DeepMatter Group Plc (AIM: DMTR, “Deepmatter”, the “Group”), the international digital chemistry data company, has signed a trials agreement with Aurigene Pharmaceutical Services Limited (“Aurigene Pharmaceutical Services”), based in Hyderabad, India, to supply its DigitalGlassware® platform.
Read MoreAurigene Pharmaceutical Services is
a leading CRO/CDMO
that provides contract research, development and manufacturing services
Learning Resource
Good practices in non-clinical toxicology assessment to accelerate IND and NDA Submissions
OCTOBER 09, 2024
Continuous Flow Chemistry: A Game-Changer for Pharmaceutical Production
SEPTEMBER 17, 2024
Revolutionizing Drug Discovery with AI: A Journey into the Future of Medicine
JUNE 18, 2024
Navigating the Surge in Demand for Lipid Nano Carriers: Challenges and Future Perspectives
MAY 16, 2024
Challenges and winning strategies to develop an analytical method for Nitrosamines
MAY 15, 2024
A Brief Introduction to Click Chemistry and Bioorthogonal Chemistry
AUGUST 23, 2023
“Bathtub Chemistry” - Necessity and Aspects of Process Research
MAY 19, 2023
The importance of business continuity planning in CRDMO industry
NOVEMBER 16, 2023
Neoantigen Specific T cells For Cancer Immunotherapy
JUNE 28, 2022
Oligonucleotide as a novel class of therapeutic modality
JULY 02, 2021
The influence of formulation development and its route of administration
JANUARY 04, 2021
Application and Manufacturing of High Potent Active Pharmaceutical Ingredient (HPAPI)
JANUARY 04, 2021
Application of mPEGs in Drug Discovery and Development
JANUARY 04, 2021
Emerging Trends in Solid State Phase Peptide Synthesis
FEBRUARY 23, 2021
Small Molecules Discovery Services
Enhanced AMES Test (EAT) for Nitrosamine Impurity Risk assessment
PROTAC Research
CDMO Services
AI-assisted Drug Discovery
Overcoming challenges with cyclic peptides for In-vitro experiments and Bioanalysis
Case study: Tackling CYP 2C9 inhibition challenges
LC-MS/MS method for quantification of a highly polar, rarely encountered peptide
Aurigene's DMPK Expertise
Quantification (PK evaluation) of small anti-sense oligonucleotides (ASOs) in animal tissues and studying the effect of ASO modifications on tissue accumulation and activity
Anti-Infective Drug Discovery
Manufacturing an activated mPEG derivative
Familiarization, process optimization and non- GMP manufacturing & supply of 3.0 kg of HPAPI product
Solid dispersion development to enhance solubility and oral bioavailability for rodent toxicology studies
Delivering 3 g dose of emetic and poorly bioavailable compound for 90 days repeated dose toxicity studies in dog
Expediting early development through innovative precision capsule filling technology
Systematic formulation design - shorten development cost & time
Gastro Retentive Dosage Form
Developing a methodology for In situ perfusion based combined tissue distribution and toxicity evaluation study
Fixed Dose Combination Formulation
Development of quick quantification method for muscle injury recovery evaluation in thermal injury mice model
Designing a novel methodology for the development of a macrocyclic peptide molecule for both formulation development and pre-clinical studies
Advancing a target molecule from in vitro studies to clinical supply: An innovative scientific solution
Mitigating the manufacturing challenge of a New Chemical Entity comprising peptidomimetic molecule in order to achieve the desired scale-up
How the re-designed synthesis of a complex carbohydrate can reduce cycle time
Low yield challenges of a typical reaction
Product development in a challenging IP landscape
Mitigating technical challenges and cost impacts by improved process design
Route scouting for an enantiomerically enriched Isoflavone
PK properties of a compound and study its effect on animal (dog) model
Technology meets sustainability - How a complex API development process goes green
Immuno Oncology - Therapies and Challenges
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization
Accelerating Drug Discovery Through Innovative Partnerships
Evolution in Pharma Industry and Demand for Integrated CDMO
Peptide Development and Manufacturing
Development of novel paullone-based PROTACs as anticancer agents
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
The Impact of Nano-Suspensions on Drug Delivery: Enhancing Solubility and Therapeutic Efficacy
Visible Light Mediated One Pot Synthesis of 2,5-Disubstituted 1,3,4-Oxadiazole
Strategies for Controlling Particle Size in Injectable Nanosuspensions and Emulsions: Techniques and Future Opportunities
Development of novel paullone derivatives as selective acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease
New MCR for the Rapid Construction of Polysubstituted Pyridines in Aqua Media Using (Bu3Sn)2MoO4 as Green and Sustainable Catalyst
Identification of Degradants of Thermal and Oxidation Stress Studies of Empagliflozin and Linagliptin Tablets by HPLC-PDA and LC-MS Instrumental Techniques
Analytical Method Development and Verification of Dapagliflozin Related Substances Estimation in Dapagliflozin Tablets by RP-HPLC
A simple RP-HPLC method development and verification of the Dissolution of Bromelain-A Complex mixture of proteolytic enzymes, in delayed release tablets
A sensitive and a simple RP-HPLC method development and verification for the quantitative estimation of Cholecalciferol in tablets
A simple RP-HPLC method development and verification for the quantitative estimation of Sodium Butyrate in tablets
Formulation Development and Characterization of ION and PH Dual Activated Nasal IN-SITU Gel Containing Levodopa and Carbidopa for the treatment of Parkinson’s Disease
An efficient four-component protocol for synthesis of poly-substituted pyridines with SiO2 as a robust recyclable catalyst
Scaling Injectable Pharmaceuticals: Roadblocks And Strategies
Lyophilization Unveiled: Advancing Suspension Formulation with Cutting-edge Techniques and Innovations
Quinoline hybrid derivatives as effective structural motifs in the treatment of tuberculosis: Emphasis on structure-activity relationships
Analytical Method Development and Verification of Dapagliflozin related Substances Estimation in Dapagliflozin tablets by RP-HPLC
Sequential Decarboxylation, Substitution, Cyclization and Oxidation with Iodine-DMSO Catalytic System: A New Methodology for the Construction of Imidazoquinoxaline Motifs
Development of Novel Paullone-based PROTACs as CDK1 Degraders for the Treatment of Breast and lung Cancer
Mass Directed Purification: Accelerating drug discovery
Modulation of Stem Cell Factor by Forskolin Inhibits Progression of Tubule Interstitial Fibrosis in Mice
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
A Sensitive and a Simple RP-HPLC Method Development and Verification for the Quantitative Estimation of Cholecalciferolin Tablets
Design and Synthesis of (3′-Benzyloxy)-3-fluoro-5-(4-methylpiperazine-1-yl)-[1,1′′′′′-biphenyl]carbaldehyde and Indanone Derivatives and their Antibacterial Activity Close to Fab I Inhibitors
A versatile design and synthesis of 3’-benzyloxy)-3-flouro-5-(4-methylpiperazine-1-yl)-[1,1’-biphenyl] carbaldehyde and indanone derivatives and their anti bacterial activity close to Fab I inhibitors
A novel processes for the preparation of (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)
Development of a Stable Intravenous Injectable Formulation of Highly Hydrolytic Molecule in a Co-Crystal With a Highly Hydrophobic (A1) & Highly Hydrophilic (A2) Drug Substance
Formulation Development of Programmable Drug Delivery of Multi-Unit Systems for the Delayed and Extended Release of Fixed Dose Combination Drugs
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
Wang-OSO 3 H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
Urea as an Ammonia Surrogate in the Hantzsch’s Synthesis of Polyhydroquinolines / 1,4-dihydropyridines under Green Reaction Conditions
A Complete Recapitulation of a Drug Delivery Based on Osmotic Pressure: An Osmotic Drug Delivery System
Synacinn TM : Bacterial reverse mutation test data in five histidine-requiring strains of Salmonella Typhimurium
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation
Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones
Dhananjaya, G., AV Dhanunjaya Rao, Kazi Amirul Hossain, Venkateswara Rao Anna, and Manojit Pal. "In silico studies and β-cyclodextrin mediated neutral synthesis of 4-oxo-4, 5, 6, 7-tetrahydroindoles of potential biological interest." Tetrahedron Letters 6
Formal synthesis of Cladospolide C & epi-Cladospolide C using R- (þ)-g-valerolactone as a chiral synthon
Lipoplex-based therapeutics for effective oligonucleotide delivery: a compendious review
Amberlite-15 promoted an unprecedented aza Michael rearrangement for one pot synthesis of dihydroquinazolinone compounds
A convergent approach towards the synthesis of the 2-alkylsubstituted tetrahydroquinoline alkaloid ()-cuspareine
A diastereoselective synthesis of boceprevir's gem-dimethyl bicyclic [3.1.0] proline intermediate from an insecticide ingredient ciscypermethric acid
Synthesis of (+)-Patulolide C Using R-(+)-g-Valerolactone as a Chiral Synthon.
Novel highly selective peroxisome proliferator-activated receptor d (PPARd) modulators with pharmacokinetic properties suitable for once-daily oral dosing
A cascade reaction for the new and direct synthesis of indolofuroquinoxalines
Synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3- dihydroquinazolin-4(1H)-one via molybdenum hexacarbonyl mediated CO gas- and ligand free carbonylative reactions
An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives
A concise stereoselective synthesis of (+)-1-deoxy-6-epicastanospermine
A Simple Approach for the Synthesis of Fused Quinazoline-Based Tetracyclic Compounds via a Multicomponent Reaction Strategy
Stereoselective synthesis of (R)-() and (S)-(+)-phoracantholide I from (R)-(+)-c-valerolactone
Concise and highly stereoselective syntheses of D-fagomine and 2-epi-fagomine
A new strategy for accessing (S)-1-(furan-2-yl)pent-4-en-1-ol: a key precursor of Ipomoeassin family of compounds and C1–C15 domain of halichondrins
FeF3-catalyzed MCR in PEG-400: ultrasound assisted synthesis of N-substituted 2- aminopyridines
Development of a Chemoenzymatic Process for Dehydroepiandrosterone Acetate Synthesis
Discovery of (R,E)‑N‑(7-Chloro-1-(1-[4-(dimethylamino)but-2- enoyl]azepan-3-yl)‑1H‑benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Muta...
A metal catalyst-free and one-pot synthesis of (3,4- dihydro-2H-benzo[b][1,4]oxazin-2-yl)methanol derivatives in water
An efficient one pot synthesis of 2-amino quinazolin-4(3H)-one derivative via MCR strategy
Sulfonic acid functionalized Wang resin (Wang-OSO3H) as polymeric acidic catalyst for the eco-friendly synthesis of 2,3-dihydroquinazolin-4(1H)-ones
A short diastereoselective synthesis of cis-(2S,4S) and cis-(2R,4R)-4- hydroxyprolines
A greener approach towards double heteroarylation of N, O and S nucleophiles: synthesis of bioactive polynuclear fused Nheteroarenes
Diastereoselective total synthesis of piperidine alkaloids: (2R,5R)- 5-hydroxyhomopipecolic acid and (2R,5R,8R)-5-hydroxysedamine
Diversity oriented concise asymmetric synthesis of azasugars: a facile access to L-2,3-trans-3,4-cis-dihydroxyproline and (3S,5S)-3,4,5-trihydroxypiperidine
Discovery of O-(3-carbamimidoylphenyl)-L-serine amides as matriptase inhibitors using a fragment-linking approach
Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs)
A simple access to N-(un)substituted isoquinolin1(2H)-ones: unusual formation of regioisomeric isoquinolin-1(4H)-ones
Reactions of salicylaldehydes with activated terminal alkynes in aqueous media: synthesis of 3- substituted 4-hydroxy chromenes as potential cytotoxic agents
An oxidative amidation and heterocyclization approach for the synthesis of β-carbolines and dihydroeudistomin Y
Synthesis of tetrahedral diarylheptanoid ent-diospongin A and epimer-diospongin B by employing Julia–Kocienski olefination
Synthesis of tetrahedral diarylheptanoid ent-diospongin A and epimer-diospongin B by employing Julia–Kocienski olefination
Applications of Gage Reproducibility & Repeatability (GRR): Understanding and Quantifying the Effect of Variations from Different Sources on a Robust Process Development
Effect of Aqueous Polyethylene Glycol on 1,3-Dipolar Cycloaddition of Benzoylnitromethane/Ethyl 2-Nitroacetate with Dipolarophiles: Green Synthesis of Isoxazoles and Isoxazolines
3‑Alkoxy-pyrrolo[1,2‑b]pyrazolines as Selective Androgen Receptor Modulators with Ideal Physicochemical Properties for Transdermal Administration
Optimization of Spray Drying Process using Central Composite Design (CCD)
Formulation and Evaluation of Controlled Porosity Osmotic Drug Delivery System of Metoprolol Succinate
Design and Synthesis of Novel 2- Substituted Benzothiazole Compounds as PTP1B Inhibitors
Synthesis of enantiomerically pure N-(2,3-dihydroxypropyl)arylamides via oxidative esterification
Cu-catalyzed coupling-cyclization in PEG 400 under ultrasound: a highly selective and greener approach towards isocoumarins
Diastereoselective total synthesis of 3,6-disubstituted piperidine alkaloids, (3R,6S)-epi-pseudoconhydrine and (3R,6R)-pseudoconhydrine
Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Design and synthesis of 2-substituted benzoxazoles as novel PTP1B inhibitors
Construction of a six-membered fused N-heterocyclic ring via a new 3-component reaction: synthesis of (pyrazolo)pyrimidines/pyridinesw
Construction of a quinoline ring via a 3-component reaction in water: crystal structure analysis and H-bonding patterns of a 2-aryl quinoline
An Efficient and Practical Synthesis of Aryl and Hetaryl a-Keto Esters
Synthesis of Isoquinoline Alkaloids via Oxidative Amidation–Bischler– Napieralski Reaction
Iodine catalyzed four-component reaction: a straightforward one-pot synthesis of functionalized pyrroles under metal-free conditions
N-heterocyclic carbene-mediated hydroacylation–Sonogashira/Heck/Suzuki coupling in a single pot: A new cascade reaction
Synthesis of novel 5-alkyl/aryl/heteroaryl substituted diethyl 3,4-dihydro-2H-pyrrole-4,4-dicarboxylates by aziridine ring expansion of 2-[(aziridin-1-yl)-1-alkyl/ aryl/heteroaryl-methylene]malonic acid diethyl esters
Yb(OTf)3 catalyzed new cascade reaction: a facile assembly of fused quinazolinones
Transition metal mediated construction of pyrrole ring on 2,3-dihydroquinolin-4(1H)-one: synthesis and pharmacological evaluation of novel tricyclic heteroarenes
A Concise and Cascade Synthesis of Batracylin and Substituted Isoindolo- [1,2-b]quinazolin-12(10H)-ones
A Concise and Convergent Synthesis of Luotonin B and E
Design and Development of a Fixed Dose Combination (FDC) of Delayed-Extended Release Niacin and a Flushing Modulator For Sequential Release
Optimization of formulation and process variable of nanosuspension: An industrial perspective
A highly effective synthesis of 2-alkynyl-7-azaindoles: Pd/C-mediated alkynylation of heteroaryl halides in water
Revisiting the reaction of b-chloroacroleins with 2-aminophenol: a new observation
Tandem versus single C–C bond forming reaction under palladium–copper catalysis: regioselective synthesis of a-pyrones fused with thiophene
Palladium-mediated synthesis of 5-substituted 4-alkynylthieno[2,3-c]pyran-7-onesq
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market